The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Explanations for the high potency of HPV prophylactic vaccines
Open accessAbstract
HPV L1 virus-like particle (VLP) vaccines administered in a prime/boost series of three injections over six months have demonstrated remarkable prophylactic efficacy in clinical trials and effectiveness in national immunization programs with high rates of coverage. There is mounting evidence that the vaccines have similar efficacy and effectiveness even when administered in a single dose. The unexpected potency of one dose of these VLP vaccines may largely be attributed to structural features of the particles, which lead to the efficient generation of long-lived antigen-specific antibody-producing cells and unique features of the virus life cycle that make the HPV virions highly susceptible to antibody-mediated inhibition of infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Duration of Humoral Immunity to Common Viral and Vaccine Antigens
Amanna, I. J., Carlson, N. E., & Slifka, M. K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066092 · Cited by 1,286
A review of clinical trials of human papillomavirus prophylactic vaccines
Schiller, J. T., Castellsagué, X., & Garland, S. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.108 · Cited by 747
Self-citationSankaranarayanan, R., Prabhu, P. R., Pawlita, M., Gheit, T., Bhatla, N., Muwonge, R., Nene, B. M., Esmy, P. O., Joshi, S., Poli, U. R. R., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00414-3 · Cited by 242
Cited by
B cell memory: building two walls of protection against pathogens
Akkaya, M., Kwak, K., & Pierce, S. K. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0244-2 · Cited by 626
Chan, C. K., Aimagambetova, G., Ukybassova, T., Kongrtay, K., & Azizan, A. (2019) · Journal of Oncology · doi:10.1155/2019/3257939 · Cited by 494
Viral Nanoparticles for Drug Delivery, Imaging, Immunotherapy, and Theranostic Applications
Chung, Y. H., Cai, H., & Steinmetz, N. F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.024 · Cited by 391
Human papillomaviruses: diversity, infection and host interactions
McBride, A. A. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00617-5 · Cited by 369
Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination
Bruun, T. U. J., Andersson, A.-M. C., Draper, S. J., & Howarth, M. (2018) · ACS Nano · doi:10.1021/acsnano.8b02805 · Cited by 281
Metadata
- Authors
- Schiller, J., & Lowy, D.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 36
- Issue
- 32
- Pages
- 4768-4773
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2783088490
- Cited by
- 225
- References
- 4
- FWCI
- 14.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Explanations for the high potency of HPV prophylactic vaccines. https://app.cochat.ai/papers/10.1016/j.vaccine.2017.12.079
- The paper
- Schiller, J., & Lowy, D. (2018). Explanations for the high potency of HPV prophylactic vaccines. Vaccine. https://doi.org/10.1016/j.vaccine.2017.12.079
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.